Alprostadil (Caverject/MUSE) Missed-Dose Protocol

What "Missed Dose" Actually Means for an On-Demand Drug

Alprostadil does not follow a calendar schedule. It is taken immediately before a sexual encounter, which means the concept of a missed dose is fundamentally different from, say, a daily antihypertensive. If an encounter was planned and did not happen, no dose should be taken. Waiting for the next encounter is the correct protocol.

The FDA-approved labeling for Caverject confirms that alprostadil is indicated for use "as needed" and places no minimum interval requirement on how often you must use it, only a maximum. [1]

Why There Is No Catch-Up Dose

Taking two doses in rapid succession to "make up" for a missed event raises plasma prostaglandin E1 levels and significantly increases the risk of prolonged erection. A 1999 study in the Journal of Urology (N=683) found that priapism occurred in approximately 1% of patients during in-office titration, with the risk directly correlated to dose escalation rather than frequency of prior use. [2]

The 24-Hour Rule and the 3-Times-Per-Week Cap

The product labeling and the American Urological Association (AUA) 2018 guideline on erectile dysfunction both specify that alprostadil injections should not be used more than once in any 24-hour period and no more than three times per week. [3] Exceeding this ceiling does not produce a therapeutic benefit and increases fibrosis risk at the injection site. [4]

How Alprostadil Works: Mechanism of Action

Alprostadil is a synthetic form of prostaglandin E1. It binds to EP2 and EP3 receptors on smooth muscle cells in the corpus cavernosum, activating adenylyl cyclase and raising intracellular cyclic AMP (cAMP). [5] Elevated cAMP activates protein kinase A, which phosphorylates myosin light-chain kinase and forces smooth muscle relaxation.

Downstream Vascular Effects

Smooth muscle relaxation dilates the helicine arteries and the sinusoidal spaces of the corpora. Increased arterial inflow compresses the subtunical venular plexus against the tunica albuginea, trapping blood and producing a rigid erection. This process is called the corporo-occlusive mechanism and it operates independently of nitric oxide signaling. [6]

Why Alprostadil Works When PDE5 Inhibitors Fail

PDE5 inhibitors (sildenafil, tadalafil, vardenafil) require intact nitric oxide release from penile endothelium. Patients with severe vascular disease, radical prostatectomy, or diabetic neuropathy often have blunted NO production. Alprostadil bypasses that pathway entirely by acting directly on smooth muscle cAMP. [5]

Linet et al. Published the key NEJM trial in 1996 (N=296 men with refractory ED who had failed prior treatment). Intracavernosal alprostadil produced a satisfactory erection in 94.0% of in-office test injections and 87.0% of at-home injections, compared with 10.9% for placebo injections. [7] This trial established alprostadil as the standard of care for PDE5-refractory disease.

MUSE vs. Caverject: Mechanistic Differences in Delivery

MUSE (Medicated Urethral System for Erection) delivers alprostadil as a small pellet into the urethra. The drug absorbs through the urethral mucosa into the corpus spongiosum, then diffuses into the corpora cavernosa. Because absorption is indirect, bioavailability is lower: MUSE typically requires doses of 125 to 1000 mcg to achieve effects similar to 5 to 40 mcg injected directly. [8] A randomized trial published in the New England Journal of Medicine in 1997 (N=1,511) found that 64.9% of MUSE patients had successful intercourse at least once, compared with 18.6% in the placebo group. [9]

Correct Dosing Protocol: Injection (Caverject)

The titration protocol for intracavernosal alprostadil is standardized across the AUA guideline and the Caverject package insert. Starting doses depend on the underlying etiology of ED. [3]

Starting Doses by Etiology

• Neurogenic ED (spinal cord injury, post-prostatectomy): start at 1.25 to 2.5 mcg.
• Vasculogenic or mixed-etiology ED: start at 2.5 to 5 mcg.
• Psychogenic ED: start at 2.5 to 5 mcg.

Each subsequent in-office titration step increases the dose by 2.5 to 5 mcg, with at least a 1-hour observation window to confirm erection duration does not exceed 1 hour. [1]

Injection Site and Technique

Inject into the lateral aspect of the proximal third of the penis (the 3 or 9 o'clock position) to avoid the dorsal neurovascular bundle and the urethra. The needle should be 27 to 30 gauge, half-inch. Rotate sides with each use to minimize fibrosis risk. [4]

A 2002 long-term follow-up study (median 24 months, N=122) found that penile fibrosis occurred in 7.8% of men who used intracavernosal alprostadil chronically, with poor injection technique identified as the primary modifiable risk factor. [4]

What to Do If a Dose Is Accidentally Doubled

If a patient inadvertently injects twice before realizing the error, the clinical priority is monitoring erection duration. Any erection persisting beyond 4 hours requires aspiration of blood from the corpora and possible intracavernosal injection of a sympathomimetic agent such as phenylephrine. [10] The AUA recommends phenylephrine as the first-line agent for priapism reversal because of its selective alpha-1 activity and lower cardiac risk compared with epinephrine. [10]

Correct Dosing Protocol: MUSE (Urethral Suppository)

MUSE is available in four dose strengths: 125 mcg, 250 mcg, 500 mcg, and 1,000 mcg. The starting dose is 250 mcg for most patients, with upward titration based on response. [9]

Administration Steps

1. Urinate before administration to moisten the urethra and improve absorption.
2. Insert the applicator approximately 3.2 cm into the urethra.
3. Press the button to release the pellet, then hold for 5 seconds.
4. Roll the penis between the palms for 10 seconds to distribute the drug.
5. Stand or walk for 10 minutes to aid absorption.

A 2004 comparative study found that urethral discomfort (burning or aching) occurred in 35.7% of MUSE users and was the primary reason for discontinuation. [11] Dose reduction to 125 mcg with slower titration reduced this adverse effect in roughly half of affected patients.

MUSE Frequency Limits

The same 3-times-per-week, once-per-24-hour ceiling applies to MUSE. The urethral mucosa does not regenerate faster than the corpora, and repeated dosing in a short window may cause local irritation and urethral bleeding. [8]

Priapism: The True Dose-Related Emergency

Priapism is the most serious complication of alprostadil use and the clinical scenario most directly tied to dosing errors. The condition is defined as an erection lasting longer than 4 hours in the absence of sexual stimulation. [10]

Time-to-Action Thresholds

• 0 to 4 hours: oral pseudoephedrine 60 mg may be attempted at home (off-label, low evidence).
• 4 to 6 hours: emergency department visit required; aspiration plus phenylephrine injection.
• Beyond 6 hours: risk of ischemic damage to erectile tissue rises sharply; permanent ED becomes likely if untreated beyond 24 to 36 hours. [10]

A 2021 review in the Journal of Sexual Medicine analyzed outcomes in 190 priapism cases treated with intracavernosal phenylephrine. Detumescence was achieved in 93.2% of patients who presented within 6 hours, dropping to 61.4% in those presenting at 6 to 24 hours. [12]

Phenylephrine Reversal Protocol

The AUA 2021 guideline update specifies phenylephrine 100 to 500 mcg intracavernosal every 3 to 5 minutes, to a maximum of 1,000 mcg per session. [10] Dilute phenylephrine 1 mg/mL to a concentration of 100 to 500 mcg/mL using normal saline before injection.

The HealthRX clinical team uses a simple three-tier triage framework for alprostadil-related erection duration concerns:

Tier 1 (2 to 3.9 hours, patient at home): Monitor. Attempt light walking and cold compress. No medication needed. Tier 2 (4 to 5.9 hours): Call the prescribing provider and proceed to the nearest emergency department. Bring the alprostadil prescription label. Tier 3 (6 hours or longer): Call 911 or go directly to the emergency department. Do not wait for a callback.

Drug Interactions That Change Dosing Risk

Alprostadil has no classic pharmacokinetic drug-drug interactions because it is metabolized locally in the lung (after systemic absorption) by 15-hydroxy-prostaglandin dehydrogenase. [5] However, pharmacodynamic interactions matter considerably.

Anticoagulants and Antiplatelet Agents

Patients taking warfarin, apixaban, or dual antiplatelet therapy (aspirin plus clopidogrel) have a higher risk of injection-site hematoma. The AUA guideline does not list anticoagulation as a contraindication but recommends careful technique and firm pressure for at least 3 to 5 minutes after each injection. [3]

Vasoactive Combinations

Combining alprostadil with other vasoactive agents, including topical nitroglycerin, intraurethral papaverine, or the Trimix formulation (papaverine, phentolamine, alprostadil), requires specialist supervision. Trimix is not FDA-approved as a fixed combination; each component is compounded. A 2016 retrospective study (N=216) found Trimix produced satisfactory erections in 92.1% of men who had failed alprostadil monotherapy, but the priapism rate was 3.7% versus 0.9% for alprostadil alone. [13]

PDE5 Inhibitors Taken Concurrently

Combining a PDE5 inhibitor with intracavernosal alprostadil is not recommended without specialist oversight. Both agents lower penile vascular resistance through different pathways, and the additive effect raises priapism risk in an unpredictable dose-dependent manner. [6]

Titration After a Dosing Gap

A patient who has used alprostadil successfully at a given dose and then stops for 6 or more months should restart at a lower dose, not return to the previous maintenance dose. Penile smooth muscle tone and vascular reactivity change with inactivity and with progression of the underlying vascular disease.

Recommended Restart Protocol

The HealthRX medical team follows an adapted version of the AUA titration guidance [3]:

• Gap of 1 to 3 months: resume at the last effective dose, but perform the first use in a clinical setting if possible.
• Gap of 3 to 6 months: step down one dose increment (for example, from 20 mcg to 15 mcg) and re-titrate upward over two to three sessions.
• Gap exceeding 6 months: restart titration from the beginning under in-office supervision.

There is currently no published randomized trial defining the optimal restart protocol for alprostadil after a prolonged gap. This recommendation is derived from consensus guidance and the known pharmacodynamics of PGE1 receptor sensitivity. [5]

Storage, Stability, and What Happens If You Use a Degraded Dose

Caverject powder for injection requires reconstitution and should be used within 24 hours of reconstitution if stored at room temperature. Caverject Impulse (dual-chamber syringe) is stable at room temperature (below 25°C or 77°F) for up to 3 months but should not be frozen. [1]

Consequences of Using Degraded Alprostadil

Degraded alprostadil loses potency. A patient who uses a dose from an improperly stored vial may experience a weak or absent erection. The appropriate response is not to inject a second dose but to discard the vial, obtain fresh product, and use the correct dose at the next encounter. [1]

MUSE suppositories should be stored in a refrigerator (2 to 8°C) and are stable at room temperature for up to 14 days. [8] Suppositories left in a hot car or exposed to temperatures above 30°C may melt or lose structural integrity, reducing urethral delivery accuracy.

Monitoring and Long-Term Safety

Patients on long-term intracavernosal alprostadil require periodic clinical review. The AUA recommends a follow-up visit at 3 months and then annually to assess for fibrotic nodules, curvature change, and injection technique. [3]

Penile Fibrosis Surveillance

Palpate the corpora at each visit. Any palpable plaque or new penile curvature warrants imaging. Penile ultrasound can detect subclinical fibrosis before it causes curvature or pain. If Peyronie's-like changes develop, the injection regimen should be paused and the patient referred for further evaluation. [4]

Cardiovascular Monitoring

Alprostadil causes systemic vasodilation when absorbed beyond the local tissue. Blood pressure drops of 5 to 10 mmHg have been recorded in clinical studies. [7] Patients with baseline hypotension (systolic <90 mmHg) or those on three or more antihypertensive agents need cardiovascular clearance before initiating alprostadil therapy. The Princeton III Consensus (2012) recommends stratifying patients by cardiovascular risk before prescribing any erectogenic agent. [14]

Liver and Renal Dose Adjustment

No dose adjustment is required for hepatic impairment because alprostadil is metabolized locally in the cavernous tissue and in the pulmonary vasculature, not primarily by hepatic CYP enzymes. [5] Renal impairment does not alter local pharmacokinetics either, though patients with renal failure often have coexisting cardiovascular disease that changes the risk-benefit calculation. [3]

Patient Instructions: A Practical Checklist

The following checklist consolidates the dosing protocol into actionable steps a patient can follow before each use.

Before each use:

• Confirm it has been at least 24 hours since the last dose.
• Confirm this is not the fourth dose in a single week.
• Inspect the vial or suppository for signs of degradation (discoloration, melting, crystallization).
• Wash hands and prepare a sterile field for injection users.

During use:

• Inject at the 3 or 9 o'clock position, rotating sides each time.
• Apply firm pressure for 3 to 5 minutes after injection.
• For MUSE, urinate first, then stand or walk after pellet insertion.

After use:

• Note erection onset (typically 5 to 20 minutes for injection, 10 to 30 minutes for MUSE).
• If erection persists beyond 3 hours with no signs of resolving, begin the Tier 2 protocol above.
• Document dose, response quality (scale 1 to 5), and any adverse effects for review at the next clinical visit.